Global Blood Therapeutics Finds $40.7M For Sickle Cell Treatments
San Francisco-based Global Blood Therapeutics said this week that it has raised $40.7M in a Series A financing, for its efforts to develop oral, small molecule drugs for treating conditions such as sickle cell disease. The funding came from Third Rock Ventures. Global Blood's founders include Charles Homcy, and Craig Muir of Third Rock, David Phillips, co-founder of COR Therapeutics, and University of California, San Francisco researchers Matthew Jacobson, Andrej Sali, and Jack Taunton.
posted on Friday, June 15, 2012 (Link to more information)
Related companies:
Global 1 Source Group
Related stories:
> Global Blood Therapeutics Finds $48M
> Iconic Therapeutics Finds $20M
> Adheron Therapeutics Acquired By Roche For $105M
> Audentes Therapeutics Gets $42.5M For Rare Diseases
> Tizona Therapeutics Finds $43M In Series B
silicontap.com Home